Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Illerhaus

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
The New England Journal of Medicine|January 22, 2025
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal CancerJens Hoeppner, Thomas Brunner, Claudia Schmoor, et al.
The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.
Hemasphere|June 24, 2026
Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphomaJulia C Kuehn, Lauritz Miarka, Roman Sankowski, et al.
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|December 25, 2015
Targetable genetic features of primary testicular and primary central nervous system lymphomasBjoern Chapuy, Margaretha G M Roemer, Chip Stewart, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Leukemia|May 13, 2022
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Nature Communications|August 10, 2024
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccinePauline Latzer, Henning Zelba, Florian Battke, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
The New England Journal of Medicine|January 22, 2025
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal CancerJens Hoeppner, Thomas Brunner, Claudia Schmoor, et al.
The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.
Hemasphere|June 24, 2026
Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphomaJulia C Kuehn, Lauritz Miarka, Roman Sankowski, et al.
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|December 25, 2015
Targetable genetic features of primary testicular and primary central nervous system lymphomasBjoern Chapuy, Margaretha G M Roemer, Chip Stewart, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Leukemia|May 13, 2022
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Nature Communications|August 10, 2024
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccinePauline Latzer, Henning Zelba, Florian Battke, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Pageof 8